Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-22

Study Completion Date

2025-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

To assess the long-term safety and tolerability in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088

Secondary Objective:

To assess, in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088:

* The long-term effect of SAR445088 on complement mediated hemolysis
* The long-term pharmacodynamics (PD) effect of SAR445088 relating to complement inhibition
* The long-term pharmacokinetic (PK) profile of SAR445088
* The long-term immunogenicity of SAR445088

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

NCT05132127

Cold Agglutinin Disease

COMPLETED PHASE3

Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

NCT02689986

Cold Agglutinin Disease Autoimmune Hemolytic Anemia

COMPLETED PHASE2

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

NCT03347422

Cold Agglutinin Disease

COMPLETED PHASE3

Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

NCT05935202

Hereditary Red Blood Cell Disorder (Disorder)

NOT_YET_RECRUITING PHASE2

Therapy for Chronic Cold Agglutinin Disease

NCT00373594

Cold Agglutinin Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The screening period for this study is up to 6 weeks. The treatment period for this study will continue for 2 years after last participant entered Part 2 (either having switched from Part 1 or as a SAR445088-naïve participant), or until SAR445088 development is discontinued, whichever comes first.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Haemolytic Anaemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAR445088

Repeat dose of SAR445088

Group Type EXPERIMENTAL

SAR445088

Intervention Type DRUG

Pharmaceutical form: solution for injection

Route of administration: IV and SC (Part 1) IV (Part 2)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SAR445088

Pharmaceutical form: solution for injection

Route of administration: IV and SC (Part 1) IV (Part 2)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female adult patients ≥18 years of age with CAD who were previously treated with SAR445088 and met criteria the below criteria for entry into Part 1:

* met the eligibility criteria of a previous study evaluating SAR445088;
* successfully enrolled and completed dosing in a previous study evaluating SAR445088;
* successfully completed end of study procedures in a previous study evaluating SAR445088; and
* per Investigator judgement, had a favorable benefit-to-risk profile after receiving SAR445088.
* OR were never treated with SAR445088 before entering Part 2, and met the below criteria to establish CAD diagnosis:

* chronic hemolysis;
* polyspecific direct antiglobulin test (DAT) positive status;
* monospecific DAT strongly positive for C3d;
* cold agglutinin \[CAg\] titer ≥64 at 4°C;
* IgG DAT ≤1+;
* hemoglobin level ≤10 g/dL;
* elevated bilirubin not attributable to liver disease;
* Documented vaccinations against encapsulated bacterial pathogens given within five years of enrollment and at least 14 days prior to dosing (vaccinations have to be initiated at least 14 days prior to dosing and completed before Week 5 of Part 2).
* Contraception (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
* Having given written informed consent prior to undertaking any study-related procedure.

Exclusion Criteria

* Cold agglutinin syndrome secondary to infection, rheumatologic disease, or known high-grade hematologic malignancy, or known solid organ tumor.
* Clinically relevant infection within 1 month of enrollment.
* Clinical diagnosis of systemic lupus erythematosus (SLE).
* Treatment with anti-CD20 monotherapy within 3 months or anti-CD20 combination therapies within 6 months prior to screening.
* Concurrent treatment with systemic immunosuppressive agents targeting B- or T-cell function and/or cytotoxic agents within 3 months prior to screening. Concurrent treatment with other systemic immunosuppressants within 5.5 half-lives of the drug prior to screening.
* Any specific complement system inhibitor other than SAR445088 (eg, eculizumab) within 3 months prior to screening.
* Concurrent treatment with systemic corticosteroids other than a stable daily dose equivalent to ≤10 mg/day prednisone within 3 months prior to screening.
* History of hypersensitivity to SAR445088 or any of its components.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No